{"transactions":[{"id":748731,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:25:05.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":59701,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant."}],"balance_after":231145,"source":{"system":"sec-edgar","filing":"0001379372-26-000002","document":"wk-form4_1780691103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000137937226000002/wk-form4_1780691103.xml","form_type":"4"}},{"id":893614,"issuer":{"id":6633,"kind":"organization","name":"Quantum Cyber N.V."},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-02-19T22:16:48.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"19,700 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026."}],"balance_after":64700,"source":{"system":"sec-edgar","filing":"0001213900-26-018502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874252/000121390026018502/ownership.xml","form_type":"4"}},{"id":1120396,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:05:48.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":49796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant."}],"balance_after":171444,"source":{"system":"sec-edgar","filing":"0001628280-25-029981","document":"wk-form4_1749240341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000162828025029981/wk-form4_1749240341.xml","form_type":"4"}},{"id":1412195,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-09T21:48:14.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":27.052,"value":270520.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.02 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":121648,"source":{"system":"sec-edgar","filing":"0001379372-24-000002","document":"wk-form4_1725918488.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000137937224000002/wk-form4_1725918488.xml","form_type":"4"}},{"id":1487592,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:54:41.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":15695,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant."}],"balance_after":131648,"source":{"system":"sec-edgar","filing":"0001628280-24-027334","document":"wk-form4_1717793673.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000162828024027334/wk-form4_1717793673.xml","form_type":"4"}},{"id":1858456,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-06-12T21:13:47.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":5466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date."}],"balance_after":5466,"derivative":{"exercise_price":0.5,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":5466},"source":{"system":"sec-edgar","filing":"0001209191-23-036374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919123036374/doc4.xml","form_type":"4"}},{"id":1870915,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T22:05:02.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":15151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person made prior Section 16 filings under CIK 0001471714"}],"balance_after":115953,"source":{"system":"sec-edgar","filing":"0001379372-23-000002","document":"wk-form4_1685743492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000137937223000002/wk-form4_1685743492.xml","form_type":"4"}},{"id":1880820,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-23T12:33:54.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over three years from the grant date."}],"balance_after":190000,"derivative":{"exercise_price":0.46,"expiration_date":"2033-05-19","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001209191-23-031639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919123031639/doc4.xml","form_type":"4"}},{"id":2246006,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heinrich","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-03T21:25:37.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant."}],"balance_after":100802,"source":{"system":"sec-edgar","filing":"0001628280-22-016216","document":"wf-form4_165429152058899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000162828022016216/wf-form4_165429152058899.xml","form_type":"4"}},{"id":4065682,"issuer":{"id":169521,"kind":"organization","name":"Ignyta, Inc.","symbol":"RXDX"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heiner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T20:28:49.000Z","date":"2018-02-08","kind":"disposition_to_issuer","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition of the Issuer by Roche Holdings, Inc. (\"Parent\") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. (\"Merger Sub\") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the \"Shares\") for a purchase price of $27.00 per Share (the \"Merger\"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":8.35,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-009141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919118009141/doc4.xml","form_type":"4"}},{"id":4065681,"issuer":{"id":169521,"kind":"organization","name":"Ignyta, Inc.","symbol":"RXDX"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heiner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T20:28:49.000Z","date":"2018-02-08","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition of the Issuer by Roche Holdings, Inc. (\"Parent\") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. (\"Merger Sub\") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the \"Shares\") for a purchase price of $27.00 per Share (the \"Merger\"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":5.75,"expiration_date":"2026-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-009141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919118009141/doc4.xml","form_type":"4"}},{"id":4065680,"issuer":{"id":169521,"kind":"organization","name":"Ignyta, Inc.","symbol":"RXDX"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heiner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T20:28:49.000Z","date":"2018-02-08","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition of the Issuer by Roche Holdings, Inc. (\"Parent\") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. (\"Merger Sub\") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the \"Shares\") for a purchase price of $27.00 per Share (the \"Merger\"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":6.76,"expiration_date":"2026-03-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-009141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919118009141/doc4.xml","form_type":"4"}},{"id":4065679,"issuer":{"id":169521,"kind":"organization","name":"Ignyta, Inc.","symbol":"RXDX"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heiner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T20:28:49.000Z","date":"2018-02-08","kind":"disposition_to_issuer","acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition of the Issuer by Roche Holdings, Inc. (\"Parent\") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. (\"Merger Sub\") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the \"Shares\") for a purchase price of $27.00 per Share (the \"Merger\"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":6,"expiration_date":"2023-12-16","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-18-009141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919118009141/doc4.xml","form_type":"4"}},{"id":4065678,"issuer":{"id":169521,"kind":"organization","name":"Ignyta, Inc.","symbol":"RXDX"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heiner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T20:28:49.000Z","date":"2018-02-08","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition of the Issuer by Roche Holdings, Inc. (\"Parent\") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. (\"Merger Sub\") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the \"Shares\") for a purchase price of $27.00 per Share (the \"Merger\"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":1.02,"expiration_date":"2023-09-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-009141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919118009141/doc4.xml","form_type":"4"}},{"id":4065677,"issuer":{"id":169521,"kind":"organization","name":"Ignyta, Inc.","symbol":"RXDX"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heiner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T20:28:49.000Z","date":"2018-02-08","kind":"disposition_to_issuer","acquired":false,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition of the Issuer by Roche Holdings, Inc. (\"Parent\") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. (\"Merger Sub\") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the \"Shares\") for a purchase price of $27.00 per Share (the \"Merger\"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":0.18,"expiration_date":"2022-02-01","underlying":"Common Stock","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001209191-18-009141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919118009141/doc4.xml","form_type":"4"}},{"id":4277108,"issuer":{"id":169521,"kind":"organization","name":"Ignyta, Inc.","symbol":"RXDX"},"owners":[{"id":41113,"kind":"person","name":"Dreismann Heinrich","position":1,"cik":"0001379372","reported_name":"Dreismann Heiner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-20T00:10:12.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (6/13/2018), or the next annual meeting of the stockholders, if earlier, subject to the reporting person's continued service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":8.35,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-040963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379372/000120919117040963/doc4.xml","form_type":"4"}}]}